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Background: Hypo-fractionated external beam radiotherapy with narrow CTV-PTV margins is increasingly applied
for prostate cancer. This demands a precise target definition and knowledge on target location and extension
during treatment. It is unclear how increase in fraction size affects changes in prostate volume during treatment.
Our aim was to study prostate volume changes during extreme hypo-fractionation (7 × 6.1 Gy) by using
sequential MRIs.
Methods: Twenty patients treated with extreme hypo-fractionation were recruited from an on-going prospective
randomized phase III trial. An MRI scan was done before start of treatment, at mid treatment and at the end of
radiotherapy. The prostate was delineated at each MRI and the volume and maximum extension in left-right,
anterior-posterior and cranial-caudal directions were measured.
Results: There was a significant increase in mean prostate volume (14%) at mid treatment as compared to
baseline. The prostate volume remained enlarged (9%) at the end of radiotherapy. Prostate swelling was most
pronounced in the anterior-posterior and cranial-caudal directions.
Conclusions: Extreme hypo-fractionation induced a significant prostate swelling during treatment that was still
present at the time of last treatment fraction. Our results indicate that prostate swelling is an important factor to
take into account when applying treatment margins during short extreme hypo-fractionation, and that tight
margins should be applied with caution.
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The field of radiotherapy (RT) is rapidly evolving with new
advanced treatment techniques and improved imaging.
Implementation of magnetic resonance imaging (MRI) for
segmentation together with sophisticated image guided
radiotherapy (IGRT) techniques based on implanted fidu-
cials has resulted in improved accuracy and precision in
RT for prostate cancer [1-3]. A workflow based solely
on MR, i.e. from prostate delineation to treatment planning
and delivery, has been proposed and shown to reduce
systematic uncertainties considerably compared to a con-
ventional CT/MR-based workflow [4]. Evidence from pros-
tate cancer radiotherapy trials shows that dose-escalation* Correspondence: adalsteinn.gunnlaugsson@skane.se
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distribution, and reproduction in any mediumimproves outcome [5-8] with limited increase in toxicity
[9,10]. The latter is partly due to a reduction of the CTV-
PTV margins compared with those applied when position-
ing the treatment beams based on skin marks or on bony
structures [11]. In addition, inter-fraction and intra-fraction
prostate motion have been studied extensively during
recent years [12-14]. However, the optimal CTV-PTV
margin in a specific setting is still debated [15]. When
the margin is reduced to as small as 3 mm, adequate
coverage of at least larger prostates seems to be jeopar-
dized [16,17].
The CTV-PTV margin should not only take setup
variations and tumour motion into account but also in-
clude any changes in the shape and size of the CTV [18].
Changes in prostate morphology during radiotherapy are
not well studied. There is some evidence that prostate
size increases slightly during the first week(s) after startCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patient baseline characteristics (n = 20)
Age









Mean (SD) 10.2 (4.5)
Prostate volume (cm3)*
Mean (SD) 73 (30)
*As segmented on CT.
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substantially during treatment and shrinks to below
baseline by the end of treatment [19,20].
Hypo-fractionated RT of prostate cancer has earned
increased attention due to a proposed low α/β value, close
to 1.5 Gy [21,22]. The application of higher fraction doses
might result in a larger change in prostate shape and size
as compared with conventional fractionation, since prostate
swelling is known to occur during brachytherapy [23,24].
The aim of the present study was to measure any
changes in prostate size during a course of extreme
hypo- fractionation delivered with external beam technique
by using sequential MRI scanning before, during and at
the end of the RT course. A cohort of patients from a
Swedish multicentre trial (HYPO-RT-PC), studying ex-
treme hypo-fractionation, was used for the study.
Methods
Patients
Twenty patients treated with extreme hypo-fractionation
were included in the present study. All patients were
recruited from an on-going Scandinavian prospective
randomized phase III trial (HYPO-RT-PC), which com-
pares extreme hypo-fractionation with conventional frac-
tionation in intermediate risk prostate cancer patients [25].
This study was approved by the local ethics committee
(Division of Oncology, Department of Clinical Sciences,
Lund University) and is performed according to the Helsinki
Declaration of 1975, (revised in 2000). Inclusion criteria
are: age < 75 years, WHO performance status 0–2, inter-
mediate risk prostate cancer with clinical category T1c-T3a
with one of the following risk factors: 1) T3a, 2) Gleason ≥
7 or 3) PSA > 10 μg/L. PSA shall be < 20 μg/L and a
biopsy-proven adenocarcinoma without any signs of spread
distally or to lymph nodes are also required. Any earlier
treatment for prostate cancer, previous hormonal therapy,
other serious diseases (including prior malignant disease),
conditions that could prevent implantation of markers into
the prostate or signs of metastatic disease are exclusion
criteria. Patient characteristics for the cohort in the present
study are given in Table 1.
Treatment
In the HYPO-RT-PC study, patients are randomized
between either conventional fractionation (39 × 2.0 Gy =
78.0 Gy given once a day, five days per week) or to an
experimental arm with an extreme hypo-fractionated
regimen (7 × 6.1 Gy = 42.7 Gy given every other weekday,
and always including two weekends without RT). The trial
arms are equieffective assuming α/β = 3 Gy, neglecting
any influence of the difference in total treatment time.
Both 3D-conform radiotherapy (3D-CRT) and IMRT/
VMAT techniques are allowed. Hormonal treatment is
not permitted.Radiotherapy procedure according to the HYPO-RT-PC
study protocol
Three gold markers were implanted into the prostate for
daily image guidance at least three weeks before the treat-
ment planning CT to avoid post-implant oedema of the
gland. Target and OAR definitions were according to
ICRU [18,26,27]. The CTV, i.e. prostate (no seminal
vesicles), was segmented as visualised on the treatment-
planning CT (slice thickness ≤ 3 mm). CT defined prostate
segmentation is mandatory according to the study protocol
but MRI is recommended as an aid for target delineation.
The PTV includes CTV with a 7 mm isotropic 3D-margin.
The CT-based CTV volume for the patients included in the
present study was already defined within the clinical trial
by three different senior radiation oncologists.
Sequential MRI scanning for CTV delineation
The patients were imaged with a Siemens Espree 1.5 T
MR scanner (Siemens Medical, Erlangen, Germany) using
a body coil and a T2 weighted high-resolution 3D se-
quence with axial slices (slice thickness 1.7-3.3 mm).
This MRI sequence is used in clinical routine as aid for
the CT-based target definition. The patients were placed
in supine position with a leg fixation device on a flat table-
top insert during the MR imaging, i.e. in the same position
as for RT.
MRI scans were performed at baseline (MRIbaseline) when
the patient came for treatment-planning CT, in the middle
(MRImid, EQD23 = 33 Gy) and at the end of treatment
(MRIend, EQD23 = 67 Gy). The MRI studies were trans-
ferred to the treatment planning system (Nucletron Oncen-
tra, ver 4.0) where the prostate was delineated in each MRI
slice by the same radiation oncologist (AG). This delineation
was done in a blinded fashion. The volume, as calculated
by the treatment planning system, was registered for each
CTVMRI. In addition, the maximum extension of the
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principal directions, i.e. left-right (xmax), anterior-posterior
(ymax) and cranial-caudal (zmax) to estimate any changes in
size in the three directions. The xmax, ymax and zmax values
are hence the sides of the smallest rectangular prism
which precisely contains the segmented prostate.
To test whether the average change in prostate volume at
the various time points was significant, a standard two-sided
t-test was used. A p-value < 0.05 was considered significant.
Results
Segmented absolute prostate volumes together with rela-
tive prostate volume changes vs. the baseline MRI volume
are given in Table 2. The results are also presented graphic-
ally in Figure 1. The prostate volumes measured on the
treatment-planning CT averaged 23% larger than those
delineated on the baseline MRI (MRIbaseline). The differ-
ence was statistically significant, p = 0.0001.
The median time (range) elapsed from MRIbaseline to
MRImid and from MRIbaseline to MRIend was 8 (6–9) daysTable 2 Prostate volumes in descending order as segmented
before radiotherapy (MRIbaseline), in the middle of the treatm
Pat # CT MRIbaseline
Abs. vol. (cm3) Rel. vol. Abs. vol. (cm3)
1 35.3 1.579 22.4
2 44.5 1.369 32.5
3 33.8 0.999 33.9
4 47.8 1.105 43.3
5 45.8 1.054 43.4
6 64.8 1.455 44.5
7 71.6 1.597 44.8
8 43.5 0.906 48.0
9 79.4 1.648 48.2
10 73.0 1.511 48.4
11 59.4 1.102 53.9
12 57.0 1.037 54.9
13 –* –* 57.2
14 83.8 1.196 70.1
15 99.0 1.347 73.5
16 79.4 1.066 74.5
17 96.5 1.145 84.3
18 105.8 1.242 85.2
19 106.2 1.021 104.0
20 153.7 1.045 147.1
Mean 72.7 1.233 60.7
SD 30.4 0.232 28.7
p-value† 0.0001 0.0004 —
Relative volumes and p-values are in relation to MRIbaseline.
*Prostate was not segmented on CT as the patient had a hip prosthesis.
‡Missing data, MRI not performed.
†Paired t-test.and 16 (15–17) days, respectively. According to the sequen-
tial MRI scanning analyses, extreme hypo-fractionation
caused a 14% mean relative volume increase (p < 0.0001)
at MRImid. The mean volume increase was still present
at the time of the last treatment fraction (9% at MRIend,
p = 0.0002). There was no significant difference in mean
relative volume change between prostates above vs. below
the median CTV size, neither at MRImid (p = 0.30) nor at
MRIend (p = 0.20).
The maximum prostate dimensions (xmax, ymax and
zmax) as defined above were unchanged in the lateral
direction but increased in the anterior-posterior and
cranial-caudal directions by 2–3 mm for MRImid or
MRIend as compared with baseline (see Table 3 for details).
Corresponding data for “small” versus “large” prostate
baseline volumes are presented in Table 4.
Discussion
Variations in prostate size during a course of radiother-
apy using conventional fractionation have been studiedon the treatment planning CT and on the MR images
ent (MRImid) and at the end of treatment (MRIend)
MRImid MRIend
Abs. vol. (cm3) Rel. vol. Abs. vol. (cm3) Rel. vol.
26.7 1.191 27.2 1.217
38.6 1.187 34.9 1.074
39.0 1.151 33.1 0.976
47.5 1.098 46.2 1.067
48.9 1.126 48.7 1.122
53.3 1.198 44.1 0.991
49.8 1.112 46.6 1.040
48.7 1.015 48.0 1.000
55.5 1.152 54.4 1.129
48.9 1.011 50.1 1.037
60.8 1.128 55.2 1.023
65.3 1.189 64.4 1.172
66.6 1.166 62.2 1.089
88.7 1.265 78.0 1.112
80.0 1.088 74.1 1.008
95.5 1.282 96.2 1.291
96.8 1.148 –‡ –‡
96.3 1.131 101.4 1.190
116.8 1.123 115.6 1.112
155.0 1.054 152.9 1.040
68.9 1.141 64.9 1.089
31.3 0.070 31.9 0.084

































Figure 1 Relative prostate volume compared to baseline (MRIbaseline) at MRImid (EQD23 = 33 Gy) (squares) and at MRIend
(EQD23 = 67 Gy) (circles) for patients 1–20.
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prostate volume reduction at end of treatment (without
any anti-hormonal treatment) as compared to baseline
although with an initial volume increase [19,20,28]. Based
on the relative position of implanted electro-magnetic
transponders, King et al. showed that the prostate size
increases transiently (mean 6.1%) during the first week(s)
after start of conventional RT (total dose 81 Gy, 1.8 Gy/
fraction) and then shrinks to below baseline by the end of
treatment. The decrease in mean prostate volume was
10.9% from the first to the final day of RT. Using MRI,
Nichol et al. studied changes in prostate size during
conventionally fractionated RT (total dose 79.8 Gy,
1.9 Gy/fraction) in 25 patients. They reported a prostate
volume decrease by 0.5%/fraction. Based on CT scanning
at start and at the last week of RT (total dose 76 Gy,
2.0 Gy/fraction), Sanguineti et al. reported a mean decrease
in prostate volume of 7% in 14 patients without any anti-
hormonal treatment.Table 3 Average change in maximum prostate extension in lat
(Δzmax) direction (mean values and 95% CI)
Δxmax (mm) P Δymax
MRmid–MRbaseline 0.2 (−1.1–1.5) 0.72 3.3 (1.8
MRend–MRbaseline 0.3 (−0.9–1.4) 0.60 2.0 (0.5
MRend–MRmid 0.1 (−0.8–0.9) 0.89 −1.4 (−To our knowledge there are no earlier studies on how
extreme hypo-fractionation affects the prostate volume
during radiotherapy. The extreme hypo-fractionation regi-
men used in our study lead to a significant increase in
prostate volume after three treatment fractions (EQD23 =
33 Gy). This increase was still apparent at the end of treat-
ment after six fractions (EQD23 = 67 Gy). Our observa-
tions indicate that the enlargement of the CTV is both
larger than that known for conventional therapy and
stays enlarged during the whole treatment course. This
could be an important factor to take into account when
choosing margin size.
When using daily imaging for set up correction, a mini-
mum margin size between 1.5-3 mm to compensate for
intra-fraction motion of the prostate has been proposed as
adequate [15,16]. Our results indicate that a margin exten-
sion of similar magnitude (covering the 95% CIs in Table 3)
could be needed to take prostate swelling into account dur-
ing extreme hypo-fractionation. The analysis of prostateeral (Δxmax), anterior–posterior (Δymax) and cranial–caudal
(mm) p Δzmax (mm) p
–4.8) 0.0002 2.5 (1.0–3.9) 0.0019
–3.4) 0.010 2.0 (0.8–3.1) 0.0029
2.7–−0.1) 0.036 −0.6 (−1.7–0.6) 0.32
Table 4 Average change in maximum prostate extension in lateral (Δxmax), anterior–posterior (Δymax) and cranial–caudal
(Δzmax) direction for “small”/“large” prostate volumes, i.e. below/above median MRIbaseline volume (=50 cm
3)
Δxmax (mm) p Δymax (mm) p Δzmax (mm) p
MRmid–MRbaseline −0.5/1.0 0.24 3.3/3.3 0.98 1.9/3.0 0.44
MRend–MRbaseline −0.1/0.7 0.44 1.3/2.8 0.29 1.9/2.0 0.88
MRend–MRmid 0.0/0.0 0.41 −0.2/−0.1 0.24 0.0/−0.1 0.34
Gunnlaugsson et al. Radiation Oncology 2014, 9:22 Page 5 of 6
http://www.ro-journal.com/content/9/1/22distension showed that the prostate seemed to swell most
profoundly in the anterior-posterior and cranial-caudal
directions. This might indicate that a margin reduction
towards the rectum should be applied with caution, espe-
cially during extreme hypo-fractionation. The difference in
prostate expansion in cranial-caudal and anterior-posterior
directions on one hand and lateral direction on the other
hand could be due to the pelvic side wall acting as an
anatomic barrier [19].
Prostate swelling during brachytherapy is well known
[23,24], and thus one could expect larger swelling when
using hypo-fractionation than during conventional radio-
therapy treatment. Our study supports this and sparks
concerns that larger treatment margins are indicated with
this kind of regimen as compared with conventional treat-
ment, especially if prostate segmentation is based on MRI
only. MRI-based contouring at baseline resulted in a CTV
volume that was about 20% smaller than the volume
generated in the original treatment-planning CT which
is in concordance with an earlier study by Smith et al.
[29] who found an average difference of 16%. Inferior
soft tissue contrast on CT as compared to MRI increases
inter-observer variability in CT-based target definition
which can partly explain this difference in volume between
CT and MRI. The fact that current clinical evidence in
prostate cancer radiotherapy is generated from CT-based
target definition, implies that great care has to be taken to
compensate for prostate swelling if the segmentation and
treatment planning process is performed with MR-only
[30]. We also looked at whether patients with larger
prostate glands experienced more swelling than patients
with smaller glands. No such difference in relative prostate
volume change was observed.
To minimize multi-observer variation in prostate seg-
mentation as well as MRI-sequence based errors [31], the
same radiation oncologist did the delineation in a blinded
fashion on the same MRI-sequence at each time-point.
The fact that the prostate increased in volume at mid-
treatment as compared to baseline for all patients supports
that this is due to a true treatment induced swelling and
not a methodological error. One could also argue that
image guided set-up correction would cope with this
change in prostate shape during the course of treat-
ment. However, this correction usually involves three
markers implanted centrally in the prostate gland, and
thus it is probably adequate for prostate motion but lessadequate for taking changes in the outer boundaries of
the gland into consideration. Re-contouring of the prostate
volume followed by re-planning before each fraction could
be needed when using narrow margins (≤ 3 mm).Conclusions
Our study indicates that the prostate swells significantly
during external radiotherapy when using extreme hypo-
fractionation. This seems to be an important factor when
defining margin size for extreme hypo-fractionation sched-
ules for prostate cancer to minimize the risk of treatment
failure when using narrow margins. In order to take
prostate swelling into account when using extreme hypo-
fractionation, we conclude that up to 2 mm extra margin
could be needed if prostate segmentation is based only on
MRI. Adaptive radiotherapy with re-planning before each
fraction, which would also take changes in prostate shape
into consideration, would be optimal.
We are planning a larger study on prostate volume
change within the frame of the HYPO-RT-PC trial also
including conventional fractionation for comparison.Consent
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included in this study.
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